Reimagining Medicine

Company overview Financial review Conclusions Appendix References FINANCIAL PROFILE Raising 2023 guidance for Novartis excluding and including Sandoz Expected, barring unforeseen events; growth vs. PY in cc Innovative Medicines (IM) Novartis ex. Sandoz (IM + Corporate) Novartis incl. Sandoz (IM + Sandoz + Corporate)1 Sales expected to grow high single digit Core Oplnc expected to grow low double digit to mid-teens Sales expected to grow high single digit Core Oplnc expected to grow low double digit to mid-teens Sales expected to grow high single digit Core Oplnc expected to grow low double digit Previous guidance (from mid) (from high single to low double) (from mid) (from high single to low double) (from mid) (from high single) Key assumptions: No US EntrestoⓇ Gx at risk launch in 2023 ☐ No SandostatinⓇ LAR generics enter in the US in 2023 1. Novartis Group guidance, assuming Sandoz would remain within the Group for the entire FY 2023. Constant currencies (cc), core results are non-IFRS measures; explanation can be found on page 48 of Condensed Interim Financial Report. 22 Investor Relations | Q2 2023 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation